Neogenomics (NEO) Total Liabilities (2010 - 2026)

Neogenomics (NEO) has 17 years of Total Liabilities data on file, last reported at $566.5 million in Q2 2026.

• Quarterly Total Liabilities rose 4.93% year-over-year to $566.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $566.5 million (up 4.93% YoY) and the FY2025 annual result came in at $523.3 million, down 28.87% from the prior year.
• Total Liabilities grew to $566.5 million in Q2 2026, from $517.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $754.5 million in Q1 2022 to a low of $517.8 million in Q1 2026.
• A 5-year average of $680.1 million and a median of $731.9 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities advanced 15.96% — and 2025, when it dropped 28.87%.
• Tracing NEO's Total Liabilities over 5 years: stood at $742.0 million in 2022, then fell by 0.31% to $739.7 million in 2023, then declined by 0.54% to $735.7 million in 2024, then retreated by 28.87% to $523.3 million in 2025, then increased by 8.26% to $566.5 million in 2026.
• The last three Total Liabilities figures came in at $566.5 million (Q2 2026), $517.8 million (Q1 2026), and $523.3 million (Q4 2025), per Business Quant data.